Here we show in detail how to use surviveR to demonstrate that the levels of CD8+ tumour infiltrating lymphocytes (TILs) (quantified by IHC) in Stage III CRC, transcriptionally-inferred CRC specific consensus molecular subtypes (CMS)13 group patients (inferred using our recently published classifieRC app12 can be prognostic/predictive of patient outcomes with respect to untreated and treated CRC patients. The gene discussed is CD8A; the disease is colorectal carcinoma.